Leaflet MADOPAR HBS 100mg / 25mg modified release capsules

Product code:
W51325002
Quantity:
100
Indicated for:
Parkinson's disease
Route of administration:
oral
Substance:
levodopa + benserazide (antiparkinsonian agents)
ATC
N04BA02 — Nervous system | Dopaminergic agents | Dopa and dopa derivatives

Precautions:

Driving impairment

Driving impairment

This medicine may affect your ability to drive or use machines.

Dizziness / vertigo

Dizziness / vertigo

This medicine may cause dizziness or vertigo.

Hypotension / fall risk

Hypotension / fall risk

May lower blood pressure and increase the risk of falls.

Drowsiness / sedation

Drowsiness / sedation

This medicine may cause drowsiness or reduced alertness.

Levodopa + Benserazide is a combination medication used in the treatment of Parkinson's disease and parkinsonian syndromes. Levodopa is a precursor of dopamine, which helps compensate for the dopamine deficiency in the brain characteristic of these conditions. Benserazide is a peripheral decarboxylase inhibitor that prevents levodopa from being converted into dopamine outside the brain, thereby increasing the treatment's effectiveness and reducing side effects.

This combination helps alleviate symptoms such as tremors, muscle rigidity, bradykinesia (slowness of movement), and balance difficulties. It is important to take the medication as prescribed by a doctor, with the dosage gradually adjusted to minimize side effects.

Side effects may include nausea, vomiting, dizziness, drowsiness, or motor fluctuations (such as 'on-off' phenomena). In rare cases, hallucinations or mood changes may occur. Regular medical monitoring is essential to adjust the treatment based on the progression of the disease.

General data about MADOPAR HBS 100mg / 25mg

Substance:
levodopa + benserazide
Date of latest medicines list:
01-06-2016
Product code:
W51325002
Concentration:
100mg / 25mg
Pharmaceutical form:
modified release capsules
Quantity:
100
Product type:
Original
Prescription status:
P-6L — Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Marketing authorisation

Manufacturer:
ROCHE PHARMA AG - GERMANIA
Holder:
ROCHE ROMANIA S.R.L. - ROMANIA
Number:
13590/2020/01
Shelf life:
3 years

Pharmaceutical forms available for levodopa + benserazide

Concentrations available for levodopa + benserazide

  • 100mg/25mg
  • 200mg/50mg